A shortage listing ends. 6 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The archive — 2025
Page 68 of 68 of this archive, newest first.
The question no chromatogram has ever answered
Every certificate circulating in this market answers a question about molecules. Almost none answers a question about organisms, pyrogens, or the integrity of the seal.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Denmark health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
Shenzhen export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
What the new Denmark guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The empty half of every certificate of analysis
Every certificate circulating in this market answers a question about molecules. Almost none answers a question about organisms, pyrogens, or the integrity of the seal.
The one randomised trial that combined an incretin with supervised exercise
One randomised trial has combined a GLP-1 receptor agonist with supervised exercise. Its result is the single most useful piece of evidence in this area.
Calder Vale Peptides of Skipton closes after 24 years
A proper account of an operation that existed, and of what closing it cost.
France caps semaglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
STEP 2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Canada pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Three services, one lot, and a spread of two and a half points
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
Dual, triple, co-formulated: a taxonomy the coverage keeps collapsing
The glucagon arm raises energy expenditure and also raises hepatic glucose output. Balancing those is the whole engineering problem.
TRIUMPH-1 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Medutest result on a Hangzhou dulaglutide lot lands 3.0 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
The 14-day notice: how a compounding wind-down works in Singapore
The document is four pages. Three of them are about dates.
The arithmetic behind every identity confirmation, worked in full
A peptide has a monoisotopic mass and an average mass, they differ by several daltons at this molecular size, and a certificate that does not say which it quotes cannot be…
Hydration, protein and the two failures that compound each other
Dietary measures are widely recommended, plausible on mechanism, and supported mainly by observational data and clinical experience.
SURMOUNT-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Australia health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A supplier suspends shipping to Poland after 11 consecutive customs detentions
The route did not close because of a rule about peptides.
Priming a pen is not optional
For licensed products the in-use period is established by stability data. For a peptide reconstituted at home there is no such data, and the honest answer is that nobody…
Why "muscle-sparing" is a marketing term and not a measurement
Grading six widely repeated claims against the studies actually behind them.
Randomised withdrawal is the cleanest design in this field and the least discussed
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
What changed at WXT in January, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The online reseller trading as Adamant Research Supply closes after 4 years
A proper account of an operation that existed, and of what closing it cost.
The 7-day notice: how a compounding wind-down works in Poland
The document is four pages. Three of them are about dates.